文献速递头颈部肿瘤放疗

基线中性粒细胞与淋巴细胞比值与接受(放化疗)放疗的头颈癌患者生存及毒性的关系

Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation.
PubMed 文献 · Radiat Oncol · 2018-11-06

该回顾性队列研究纳入2007至2010年接受根治性或辅助性(放化疗)放疗的186例头颈鳞状细胞癌患者,评估治疗前10天内血常规计算的中性粒细胞与淋巴细胞比值(NLR)及血小板与淋巴细胞比值(PLR)的预后价值。PLR与结局及毒性均无关。作者认为NLR是死亡的独立预测因子,但非疾病特异性结局或毒性的预测因子。

要点

  • NLR与局部区域无复发生存、远处无复发生存及≥2级急性毒性无显著关联。
  • PLR与结局及毒性均无关联。

核心结论

  • 作者认为在头颈鳞状细胞癌患者中,NLR是死亡的独立预测因子,但不是疾病特异性结局或毒性的预测因子。
  • 作者认为NLR是一种易获取的生物标志物,可能改善治疗前预后判断并可用于风险分层。

研究设计与样本

  • 回顾性病历审查,连续纳入2007至2010年接受根治性或辅助性(放化疗)放疗的头颈鳞状细胞癌患者186例。
  • NLR和PLR基于治疗开始前10天内进行的全血细胞计数计算,作为对数转换连续变量(log NLR和log PLR)分析。
  • 采用单变量和多变量Cox回归分析,校正疾病特异性预后因素;中位随访49个月。

主要发现

  • NLR与≥2级急性毒性无显著关联。
  • PLR与结局及毒性均无关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A high neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammation and together with the platelet-to-lymphocyte ratio (PLR) is associated with worse outcomes in several solid tumors. We investigated the prognostic value of NLR and PLR in patients with head and neck squamous cell carcinoma (HNSCC) treated with primary or adjuvant (chemo)radiotherapy ((C)RT). METHODS: A retrospective chart review of consecutive patients with HNSCC was performed. Neutrophil-to-lymphocyte ratio and PLR were computed using complete blood counts (CBCs) performed within 10 days before treatment start. The prognostic role of NLR and PLR was evaluated with univariable and multivariable Cox regression analyses adjusting for disease-specific prognostic factors. NLR and PLR were assessed as log-transformed continuous variables (log NLR and log PLR). Endpoints of interest were overall survival (OS), locoregional recurrence-free survival (LRFS), distant recurrence-free survival (DRFS), and acute toxicity. RESULTS: We analyzed 186 patients treated from 2007 to 2010. Primary sites were oropharynx (45%), oral cavity (28%), hypopharynx (14%), and larynx (13%). Median follow-up was 49 months. Higher NLR was associated with OS (adjusted HR per 1 unit higher log NLR = 1.81 (1.16-2.81), p = 0.012), whereas no association could be shown with LRFS (HR = 1.49 (0,83-2,68), p = 0.182), DRFS (HR = 1.38 (0.65-3.22), p = 0.4), or acute toxicity grade ≥ 2. PLR was not associated with outcome, nor with toxicity. CONCLUSION: Our data suggest that in HNSCC patients treated with primary or adjuvant (C)RT, NLR is an independent predictor of mortality, but not disease-specific outcomes or toxicity. Neutrophil-to-lymphocyte ratio is a readily available biomarker that could improve pre-treatment prognostication and may be used for risk-stratification.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Bojaxhiu B, Templeton AJ, Elicin O, et al. Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation. Radiat Oncol. 2018. PMID: 30400969. doi:10.1186/s13014-018-1159-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。